Please complete the CAPTCHA to continue
A concise factual answer block for searchers comparing this professional profile.
Martin Braddock, Frsb, Fras is listed as Scientist specialising in technological innovation, drug discovery and clinical development from basic science through to drug approval at GENIXICONSULTING LTD, based in Nottinghamshire, England, United Kingdom. AeroLeads shows a matched LinkedIn profile for Martin Braddock, Frsb, Fras.
Martin Braddock, Frsb, Fras previously worked as Founder and Director at Genixiconsulting Ltd and Global Products Leader Symbicort Aerosphere and Established Respiratory Brands; Symbicort, Pulmicort at Astrazeneca. Martin Braddock, Frsb, Fras holds Ph.D, Radiation Biology from Mrc Radiobiology Unit Harwell, Holt Radium Institute University Of Manchester And University Of Salford.
This section adds company-level context without repeating Martin Braddock, Frsb, Fras's masked contact details.
Review company-level records connected to Martin Braddock, Frsb, Fras before choosing the right outreach path.
Accomplished leader of projects, people and science with broad BioPharma drug discovery, drug development, science and project leadership experience for > 40 projects (target identification to phase III products and Established Brands). Dual scientific and project leading; 40 years research, development and management experience (including 29 years in Drug Discovery and Development (AstraZeneca and GlaxoSmithKline) & 11 years holding academic positions, 4 years as a Royal Society University Research Fellow at Oxford University with own secured research grant funding).Drug development leader of a team with Global input (US, EU, India and China) for new respiratory products and Established Brands securing multiple regulatory submissions and product approvals.Extensive experience in drug discovery from target identification through to lead optimisation in multiple therapeutic areas, all aspects of early and late stage clinical development including LCM.Drug discovery project leader taking 8 compounds to candidate selection for first time in man.Line management experience (Discovery Bioscience Department Director, AstraZeneca, delivering biochemistry, pharmacology and translational science supporting selection of 18 small molecule and 4 biological candidate drugs); Disease Sciences Unit Head, GlaxoSmithKline, delivering cellular biology support to 6 small molecule drug candidates). Extensive project management experience.Specialties: Drug developer: leadership of multiple global product teams for in-line products, LCM and licence to operate activities for established respiratory brands.Drug hunter: small and large molecule from lead optimisation, candidate selection and phase II readout in metabolic diseases, cardio-vascular, respiratory and inflammatory/autoimmune disease, HIV and AIDS research, Alzheimer's, soft and hard tissue repair and regeneration. Early product support for multiple development projects; line and matrix management (82 people).Team builder: building, motivating and managing establishing networks of academic collaborators and clinical experts.Invited expert reviewer and advisor for multiple international grant awarding bodies- Awarded a Royal Society University Research Fellowship.- Elected Fellow of the Royal Society of Biology in recognition of contribution to biological sciences.- Invited Fellow of the Royal Society of Medicine.- Recipient of an Alumnus Achievement Award (University of Salford) for outstanding contribution to science.- Elected Fellow of the Royal Astronomical Society
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
East Midlands, England, United Kingdom
Who I am and what I have:- Experienced project leader with a proven track record of leading activities at all phases of early stage science, drug discovery and development up to 10s-100s $M projects in global roles, manager and scientist with an International scientific reputation. - Broad expertise across multiple therapeutic areas including respiratory.
Cambridge, England, United Kingdom
Leadership of a Global Product Team which delivers regulatory submissions/approvals and licence to operate maintenance activities for 9 products/brands supporting ~ $3Bn sales revenue in 2023.
Cambridge, England, United Kingdom
Team lead for our SARS-Cov-2 monoclonal antibody project
Cambridge, United Kingdom
Leadership of a Global Product Team for established respiratory brands and nebulised products for both China and International markets. Pioneered two innovative technologies to maintain medicine quality, protecting > $100M sales, supported by negotiation and agreement with multiple internal and external multiple stakeholders.
Granta Park, Cambridge UK
Project management of Tezepelumab phase III development in severe asthma and life cycle management. Co-development project with Amgen.
Granta Park, Cambridge UK
Project management of Tralokinumab phase III development in severe asthma and in leading and supporting multiple activities in preparation for regulatory submissions. Alliance Manager (until May 2017) for transition of Tralokinumab to LEO Pharmaceuticals for development in atopic dermatitis.
Global Medicines Development, Alderley Park, Macclesfield
Responsible for building and strengthen the science throughout the phase III clinical programme, aligned to the target product profile to support both the regulatory submission and the developing brand within the portfolio of late stage development candidates.Led scientific input for >10 licensing opportunities in respiratory/vascular disease/tissue repair.
Global Medicines Development, Alderley Park, Macclesfiled
Responsible for delivery of scientific support, through rigorous construction of non-clinical, translational and clinical science build for multiple late stage phase IIb and phase III clinical development projects in Inflammation, Neuroscience and Respiratory Global Medicines Development in AstraZeneca and company subsiduaries.
Charnwood R&D, Loughborough
Role includes contributing to the development of scientists in R&D Charnwood, dissemination of AstraZeneca R&D science activities to external groups and bodies involved in science education and chair of the Science Leadership Team comprising scientists from chemistry, bioscience and DMPK from both Lund and Charnwood R&D sites.
Global Medicines Development, Alderley Park, Macclesfield
Fostamatinib is a SYK inhibitor licensed by AstraZeneca from Rigel Pharmaceuticals for clinical development in rheumatoid arthritis (RA). The drug has now completed phase III clinical trials. As science lead, I had responsibility for ensuring that evolving science would support regulatory submission. In addition I developed the science plan to build the.
Charnwood R&D, Loughborough
Leader of the Global Biology Network (GBN) across all AstraZeneca research sites. The GBN is reponsible for harmonisation of processes involving bioscience in all aspects of drug discovery from pre-competitive data sharing, target identification and validation through to asset exploitation, candidate drug re-positioning, exploiting value in co-morbid.
Charnwood R&D, Loughborough
Head of Discovery Bioscience with line mangement responsibility for 82 people specialising in lead optimisation drug discovery and translational science for both small molecule and biological projects. Therapeutic areas covered are respiratory (asthma, COPD), autoimmune disease (RA) and OA with a variety of targets including chemokines, cytokines and their.
Charnwood R&D, Loughborough
Lead optimisation project leader for a P2X7 receptor antagonist drug discovery project delivering three candidate drugs into clinical development for inflammatory and respiratory disease. Most advanced; AZD9056 reached phase IIb clinical development in rheumatoid arthritis.
Charnwood R&D, Loughborough
Line management responsiility for 18 staff working on lead optimisation drug discovery projects in autoimmune disease and respiratory.
Charnwood R&D, Loughborough
Chair of a cross-functional global discipline team setting strategic direction for the inflammation research area for projects in discovery and early development.
Medicines Research Centre, Stevenage
Head of Disease Cell Biology managing pre-clinical biology supporting multiple therapeutic areas (CNS - Alzheimer's; Respiratory - Asthma, COPD; Autoimmune disease - Rheumatology; Cardiovascular; Vascular Disease Prevention).
Medicines Research Centre, Stevenage
Responsible for discovery and validation of gene therapeutic approaches for promoting tissue repair in skin and bone and for skin anti-fibrotics.
Medicines Research Centre, Stevenage
JSC member for a functional genomics strategic intitiative with Nemapharm pharmaceuticals
Medicines Research Centre, Stevenage
Team Leader in Vascular Diseases Unit responsible for basic research in vascular biology, application of gene therapy to atherosclerosis and understanding and exploitation of fluid shear stress on gene expression in human vasculature.
Retrovirus Molecular Biology Group, Biochemistry Department University Of Oxford
Research grant holder supporting basic research in HIV biology, specialising in: determination of mechanism of action studies for leading anti-viral compounds at the level of gene expression, transcriptional and translational control of HIV open reading frames, masked message control of gene expression and mRNA sub-cellular localisation of intronic.
Retrovirus Molecular Biology Group, Biochemistry Department University Of Oxford
Post-doc in the lab of Susan and Alan Kingsman working on bovine papilloma virus and HIV molecular biology: transcriptional and translational control of E2, tat and rev open reading frames.
Oxford, England, United Kingdom
Academic tutor for final year BPhil biochemistry students for modules and dissertations in molecular virology.
Medical Sciences Institute, University Of Dundee
Post-doc in the lab of Grahame Hardie and Philip Cohen; MRC Protein Phosphorylation Group, Medical Sciences Institute working on the molecular cloning of mammalian fatty acid synthetase.
Effects of high LET radiation on DNA double strand breaks with size of DNA and pulse radiolysis analysis of hydroxyl free radicals adducts.
Quick answers generated from the profile data available on this page.
Martin Braddock, Frsb, Fras works for GENIXICONSULTING LTD.
Martin Braddock, Frsb, Fras is listed as Scientist specialising in technological innovation, drug discovery and clinical development from basic science through to drug approval at GENIXICONSULTING LTD.
Martin Braddock, Frsb, Fras is based in Nottinghamshire, England, United Kingdom while working with GENIXICONSULTING LTD.
Martin Braddock, Frsb, Fras has worked for Genixiconsulting Ltd, Astrazeneca, Ministero Della Salute, Astrazeneca Pharmaceuticals, and Glaxosmithkline.
You can use AeroLeads to view verified contact signals for Martin Braddock, Frsb, Fras at GENIXICONSULTING LTD, including work email, phone, and LinkedIn data when available.
Martin Braddock, Frsb, Fras holds Ph.D, Radiation Biology from Mrc Radiobiology Unit Harwell, Holt Radium Institute University Of Manchester And University Of Salford.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts